Abstract
Bioartificial liver devices (BALs) are categorized as advanced therapy medicinal products (ATMPs) with the potential to provide temporary liver support for liver failure patients. However, to meet commercial demands, next-generation BAL manufacturing processes need to be designed that are scalable and financially feasible. The authors describe the development and application of a process economics decisional tool to determine the cost of goods (COG) of alternative BAL process flowsheets across a range of industrial scales. The decisional tool comprised an information database linked to a process economics engine, with equipment sizing, resource consumption, capital investment and COG calculations for the whole bioprocess, from cell expansion and encapsulation to fluidized bed bioreactor (FBB) culture to cryopreservation and cryorecovery. Four different flowsheet configurations were evaluated across demands, with cell factories or microcarriers in suspension culture for the cell expansion step and single-use or stainless steel technology for the FBB culture step. The tool outputs demonstrated that the lowest COG was achieved with microcarriers and stainless steel technology independent of the annual demand (1500-30 000 BALs/year...Continue Reading
References
Feb 24, 2001·Journal of Hepatology·M KhalilC Selden
Oct 7, 2006·Cost Effectiveness and Resource Allocation : C/E·Franz P Hessel
Sep 5, 2008·PharmacoEconomics·Christopher McCabeAnthony J Culyer
Mar 18, 2011·Tissue Engineering. Part C, Methods·Isobel MassieBarry Fuller
Jul 19, 2012·Biotechnology and Bioengineering·James PollockSuzanne S Farid
Sep 8, 2012·Regenerative Medicine·Devyn M Smith
Mar 22, 2013·BioResearch Open Access·Eloy ErroClare Selden
Jul 31, 2013·Biotechnology and Bioengineering·Ana S SimariaSuzanne S Farid
Dec 25, 2013·PloS One·Clare SeldenHumphrey Hodgson
Jan 15, 2014·Tissue Engineering. Part C, Methods·Isobel MassieG John Morris
Dec 24, 2014·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Otto-Wilhelm Merten
Jan 31, 2015·Health Technology Assessment : HTA·Catriona CrossanAndrew Burroughs
Aug 4, 2015·Regenerative Medicine·Sally HassanSuzanne S Farid
Nov 14, 2015·Regenerative Medicine·Tania BubelaSowmya Viswanathan
Feb 14, 2016·Archives of Toxicology·Claudia LuckertStefanie Hessel
Mar 17, 2016·Regenerative Medicine·Sally HassanSuzanne S Farid
Jun 24, 2016·Tissue Engineering. Part B, Reviews·Toon LambrechtsIoannis Papantoniou
Nov 2, 2016·Frontiers in Cell and Developmental Biology·Carla DesselsMichael S Pepper
Dec 27, 2016·Cytotherapy·Ohad KarnieliOhad Karnieli
Aug 26, 2017·PloS One·Peter KilbrideJohn Morris
Nov 8, 2017·Scientific Reports·Clare SeldenC Wendy Spearman
Jan 18, 2018·Biotechnology Journal·Jonathan HummelMark Schofield
Dec 18, 2018·Theranostics·Yi LiHong Bu
Jul 26, 2019·Journal of Translational Medicine·Ruud DasHelene Roelofs